Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glioblastoma mutliforme

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo plus Yervoy aces phase III trial

The cancer drug combo met one of its primary endpoints in NSCLC patients

- PMLiVE

Merck closes in on adjuvant melanoma indication for Keytruda

Its immunotherapy could catch up with BMS’ Opdivo if approved

Bristol-Myers Squibb (BMS) building

BMS adds another Ono drug to its immuno-oncology portfolio

Pharma giant hopes its new candidate can follow in the footsteps of Opdivo

Bristol-Myers Squibb (BMS) building

BMS adds another EU indication to Opdivo’s growing list

Wins European licence to treat high-risk advanced melanoma

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo/Yervoy combination demonstrates OS benefit

Better kidney cancer symptom control reported versus sunitinib was also reported

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo defies naysayers with healthy growth

Third quarter sales of the PD1 inhibitor saw a 38% rise

Bristol-Myers Squibb (BMS) building

NICE says OK to Opdivo for lung cancer via CDF

Comes after BMS drops the price of its PD-1 inhibitor

Cancer Research UK’s Karen Vousden to join BMS board

She will also serve on the pharma firm's Science and Technology Committee

- PMLiVE

Novartis scores but Roche misses in melanoma trials

Phase III trial combo success for Tafinlar/Mekinist “unprecedented”

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo and Yervoy ace kidney cancer trial

Combined checkpoint inhibitors show improved survival versus standard therapy

Bristol-Myers Squibb (BMS) building

BMS data add to checkpoint inhibitor combo confusion

Opdivo and Yervoy meet one objective but miss another in CheckMate-214

- PMLiVE

Biotecnol taps into Cancer Research UK network for first trial

New drug hoped to have broad activity across multiple tumour types

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links